John Allan, MD, Weill Cornell Medicine

John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.

An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.

A discussion about treatment for high-risk patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Nicole Lamanna, MD, provides an overview of Bruton's tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting.

Steven Coutre, MD, provides an overview of the phase 3 GLOW trial, as well as other novel and emerging combinations for the treatment of chronic lymphocytic leukemia (CLL).

John Allen, MD, provides an overview of data looking at emerging combinations as initial therapy for chronic lymphocytic leukemia (CLL).

Experts discuss the optimal approach for choosing between a Bruton tyrosine kinase (BTK) inhibitor–based therapy vs a BCL2 inhibitor–based regimen for frontline chronic lymphocytic leukemia (CLL) therapy.

An overview of the h ALPINE trial of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

A continuing discussion about the implications of toxicities with BTK inhibitors.

A discussion about managing toxicities associated with Bruton tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL).

Leukemia experts provide their personal experience using Bruton tyrosine kinase (BTK) inhibitors to treat patients with chronic lymphocytic leukemia (CLL) in the first-line setting.

Jennifer Woyach, MD, discusses her experience using ibrutinib for chronic lymphocytic leukemia (CLL) in the first-line setting.

An overview of prognostic models in chronic lymphocytic leukemia (CLL).

A discussion about prognostic factors in patients with newly diagnosed chronic lymphocytic leukemia (CLL).

Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).

William Wierda, MD, PhD, leads a panel of experts in a discussion pertaining to the treatment of chronic lymphocytic leukemia (CLL), beginning with the evolving treatment landscape.